Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Spirometry, a type of pulmonary ... lungs to fully expand. This includes obesity, scoliosis (abnormal curvature of the spine), diaphragmatic paralysis, and pleural effusion. Intra-thoracic restriction ...

“This exciting collaboration with GSK will help … make meaningful progress in the treatment of chronic lung diseases like pulmonary fibrosis,” Darrell Kotton, MD, CReM’s founding director and a ...

AN INSIGHTFUL session on the future of lung ... fibrosis (CF) transmembrane conductance regulator (CFTR) modulators in a population of patients with a single Phe508del allele variant, a frequent ...

Lung inflammation and injury remain a major focus of research ... capillary endocytic and trafficking events in the pathogenesis and potential therapy of pulmonary inflammation and injury. Further ...

Emily Pink, 21, has cystic fibrosis, a rare genetic disorder that causes a build-up of sticky mucus in her lungs and digestive system. She remembers a childhood filled with hospital stays brought ...

Miliary infections, being hematogenous, have a random distribution but tend to involve mainly the lower lung zones ... 2-19–2-23). Fibrosis can usually be recognized on HRCT by the presence ...